VIDEO: Photobiomodulation shows positive 24-month results in patients with dry AMD
Click Here to Manage Email Alerts
WAILEA, Hawaii — In this Healio video perspective from Retina 2024, Marion R. Munk, MD, PhD, overviews data investigating multiwavelength photobiomodulation for the treatment of dry age-related macular degeneration.
The LIGHTSITE III study, which included 148 eyes treated with either the LumiThera Valeda light delivery system or sham, met its primary outcome of achieving statistically significant improvement in visual acuity among the multiwavelength photobiomodulation cohort compared with the sham arm.
Munk also reported a statistically significant reduction in the conversion to geographic atrophy among patients with intermediate AMD.
“In summary, this was a really a very nice encouraging trial result for our patients with dry age-related macular degeneration,” Munk said.
Collapse
Munk M. LIGHTSITE III analysis: 24-month evaluation of multiwavelength photobiomodulation in dry age-related macular degeneration using the Valeda light delivery system. Presented at: Hawaiian Eye 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Read more about
Click Here to Manage Email Alerts